Home Cart Sign in  
Chemical Structure| 14605-22-2 Chemical Structure| 14605-22-2

Structure of Tauroursodeoxycholate
CAS No.: 14605-22-2

Chemical Structure| 14605-22-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tauroursodeoxycholate (TUDCA) is an endoplasmic reticulum stress inhibitor that acts as a mitochondrial stabilizer and anti-apoptotic agent, with potential in neurodegenerative diseases.

Synonyms: Tauroursodeoxycholic Acid; TUDCA; Tauroursodeoxycholic Acid, TUDCA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tauroursodeoxycholate

CAS No. :14605-22-2
Formula : C26H45NO6S
M.W : 499.70
SMILES Code : O=S(CCNC(CC[C@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C)=O)(O)=O
Synonyms :
Tauroursodeoxycholic Acid; TUDCA; Tauroursodeoxycholic Acid, TUDCA
MDL No. :MFCD00069496
InChI Key :BHTRKEVKTKCXOH-LBSADWJPSA-N
Pubchem ID :9848818

Safety of Tauroursodeoxycholate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an inhibitor targeting endoplasmic reticulum (ER) stress. It markedly lowers the levels of molecules involved in apoptosis, including caspase-3 and caspase-12. Furthermore, Tauroursodeoxycholate has an effect on suppressing ERK activity[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05753852 Amyotrophic Lateral Sclerosis PHASE3 RECRUITING 2025-03-31 Katholieke Universiteit Leuven... More >>, Leuven, Belgium|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Centre Hospitalier Universitaire Limoges, Limoges, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Centre Hospitalier Regional Universitaire de Tours, Tours, France|Charité - Universit?tsmedizin Berlin, Berlin, Germany|Universit?tsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universit?tsklinikum Jena, Jena, Germany|Universit?t Ulm, Ulm, Germany|Trinity College Dublin, Dublin, Ireland|IRCCS Istituto Auxologico Italiano, Milano, Italy|NEuroMuscular Omnicentre. Fondazione Serena Onlus, Milano, Italy|AOU Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy|IRCCS Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Italy|AOU Città della Salute e della Scienza di Torino, Torino, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom|University of Sheffield, Sheffield, United Kingdom|Royal Stoke University Hospital, Stoke, United Kingdom Less <<
NCT03878654 Asthma PHASE1 TERMINATED 2019-09-11 Vermont Lung Center, Colcheste... More >>r, Vermont, 05446, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

10.01mL

2.00mL

1.00mL

20.01mL

4.00mL

2.00mL

References

 

Historical Records

Categories